Archives: MFN News Items

iZafe Group announces exclusive agreement to sell 1,000 Dosell annually

iZafe Group AB ("iZafe Group") announce that it has signed an exclusive partnership agreement with IVE Ventures (“IVE”) for the right to exclusively sell and market the Dosell medication robot in the Netherlands. IVE has committed to purchasing a minimum of 1,000 Dosell units annually for a three-year period in order to maintain exclusivity. The total value of hardware purchases and licensing revenue amounts to approximately SEK 16 million for the first three years, with an annual recurring licensing revenue of at least SEK 6 million thereafter.

IVE has placed an initial order for 1,000 Dosell units and has a minimum commitment of 1,000 Dosell units per year to maintain exclusivity for the Netherlands.

IVE has been offering a range of connected health services since 2014. In recent years, IVE has expanded its portfolio to include products from Teltonika, Vayyar, Vivago, Eview, and Withings. IVE has chosen to include Dosell in its portfolio in order to expand its range with a groundbreaking digital medication robot. By distributing Dosell, IVE can better support its existing care and alarm center customers in the Netherlands with a reliable and proven safe medication solution. IVE aims to commercially launch Dosell in the Dutch market in the second quarter of 2023.

“This agreement is another great step forward for IVE. We have been assessing the market of providing safe and reliable medication dispensing for the past 24 months. When meeting Dosell, we quickly realized that they share the same vision to provide reliable connected health solutions. The short integration time for market introduction, that lasted only 8 weeks, solidifies our believe that our shared DNA will allow us to act and react agile on the challenges which the Healthcare industry faces today. Dosell covering a key part of our connected health portfolio, allowing us to fulfil our mission: keeping our loved ones independent and safe in the easiest, surest and most economical way.” Says Martijn Van Bree, Managing Director of IVE Ventures.

"Since we launched a consumer version of our medication robot Dosell, we have received great demand internationally. I am very pleased that we are reaching this important milestone. Breaking into the Dutch market, which is the market that has come the furthest in packaging medicine in sachets, is significant. That IVE also chooses to invest heavily in our medication robot Dosell after reviewing all competitors in the market is also a testament to the strength of Dosell's potential for international success," says Anders Segerström, CEO of iZafe Group.

About IVE Ventures

IVE Ventures was founded in 2014 to invest into, distribute and operate a range of connected services within the Smart Mobility and Connected Health sector. Within the group, IVE’s subsidiaries include a service provider for connected health services (ICE Alarm the Netherlands), a 24/7 multilingual Medical Service Center (ICE Alarm España) and a provider of smart mobility solutions for insurance companies (ICE Protect the Netherlands). Operating out of offices in both the Netherlands and Spain, IVE is trusted by several major insurance and security companies who rely on IVE to provide mission-critical solutions to its clients.

About Dosell
The medicinal robot Dosell is a Swedish-made digital aid for safer medication at home and for people living in nursing homes. Dosell is integrated into welfare platforms and is sold as one of several integrated digital aids via partners.
In a Swedish report, it is estimated that 3,000 Swedes die annually from drug-related injuries and that 6–16 percent of hospital admissions are drug-related. The costs for drug-related injuries that can be avoided are estimated at SEK 5.6–24.6 billion per year.
Dosell notifies the patient when it's time to take the medicine, and if the medicine is not taken despite the reminders, Dosell alerts healthcare professionals or relatives who can quickly prevent an injury and improve compliance, thus minimizing drug-related injuries.

Read more at www.dosell.se

Contacts

Anders Segerström, Chief Executive Officer 
E-mail:
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: 
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

This information is information that iZafe Group is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-02-27 16:30 CET.

Attachments

iZafe Group announces exclusive agreement to sell 1,000 Dosell annually

iZafe Group announces exclusive agreement to sell 1,000 Dosell annually

The subscription price for exercise of warrants of series TO13B in iZafe Group AB has been set at SEK 0.20 per share of series B, and the exercise period begins tomorrow February 23

In November 2022 iZafe Group AB ("iZafe" or the "Company") acquired Pilloxa AB and, in connection with the acquisition, carried out a directed issue of units consisting of shares of series B and warrants of series TO13B. To compensate existing shareholders for the dilution from the directed issue of units, and with the purpose of capitalizing iZafe in a favorable way, the Company issued warrants of series TO13B free of charge to all shareholders. A total of 118,556,833 warrants of series TO13B were issued. Each warrant gives the right to subscribe for one (1) new share of series B in the Company. The subscription price has been set to SEK 0.20 per share of series B. The exercise period for warrants of series TO13B runs from February 23, 2023, up to and including March 8, 2023.

Each warrant gives the right to subscribe for one (1) new share of series B in the Company. The subscription price for the warrants of series TO13B shall correspond to 70 percent of the
volume-weighted average price of the Company's share of series B on Nasdaq First North Growth Market during the measurement period from and including February 9, 2023, up to and including February 22, 2023. However, not lower than the quota value for the Company's share, corresponding to SEK 0.20, and not higher than SEK 0.30 per share. The volume-weighted average price of the Company's share of series B during the measurement period amounted to approximately SEK 0.21. Thus, the subscription price is determined to SEK 0.20. The exercise period for warrants of series TO13B runs from February 23, 2023, up to and including March 8, 2023. Complete terms and conditions for the warrants of series TO13B are available on the Company's website, www.izafegroup.com.

Summarized terms for the warrants of series TO13B:

Exercise period: February 23, 2023 – March 8, 2023.

Exercise price: SEK 0.20 per share of series B.

Issue size: 118,556,833 warrants of series TO13B, which entitles to subscription of 118,556,833 shares of series B. If all the warrants are exercised, the Company will receive approximately SEK 23.7 million before issuing costs.

Last day for trading warrants of series TO13B: March 6, 2023.

Share capital and dilution: If all warrants are exercised the share capital will increase with SEK 23,711,366.60, from SEK 30,756,066.00 to SEK 54,467,432.60. If all warrants are exercised the number of shares will increase with 118,556,833 shares of series B, in total the number of shares in the Company will increase from 153,780,330 shares to 272,337,163 shares (600,000 shares of series A and 271,737,163 shares of series B). The dilution at full exercise of all warrants amounts to approximately 43.53 percent of the number of shares and 42.69 percent of the votes in the Company.
Note that the warrants of series TO13B that are not exercised at the latest March 8, 2023, or sold at the latest March 6, 2023, will expire without value. For the warrants not to lose their value, the holder must actively subscribe for new shares or sell the warrants. Please note that some trustees may close their registration earlier than 8 March 2023.

Advisors
Mangold Fondkommission AB is the financial advisor and Eversheds Sutherland Advokatbyrå AB is the legal advisor to the Company in connection with the exercise of the warrants of series TO13B.

Contacts

Anders Segerström, Chief Executive Officer 
E-mail:
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: 
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

Attachments

The subscription price for exercise of warrants of series TO13B in iZafe Group AB has been set at SEK 0.20 per share of series B, and the exercise period begins tomorrow February 23

The subscription price for exercise of warrants of series TO13B in iZafe Group AB has been set at SEK 0.20 per share of series B, and the exercise period begins tomorrow February 23

iZafe Groups kvartalsrapport Q4, oktober-december 2022

iZafe Group AB (publ.) – presenterar idag, 3 februari, sin rapport för fjärde kvartalet.

Finansiell utveckling i sammandrag

  • Nettoomsättningen för kvartalet uppgick till 194 (220) TSEK. Kvartalets omsättning utgörs av intäkter hänförliga till försäljning av den digitala läkemedelsroboten Dosell samt av försäljning av det medicintekniska hjälpmedlet Pilloxa. Pilloxa AB förvärvades den 28 november 2022 och cirka en månads försäljning är därför inkluderat i kvartalet.
  • Rörelseresultat för kvartalet uppgick till -5 556 (-12 750) TSEK.
  • Resultat efter finansiella poster för kvartalet uppgick till -5 570 (-12 943) TSEK.
  • Periodens kassaflöde uppgick till 1 630 (17 264) TSEK. Periodens kassaflöde inkluderar nyemission, inlösen av teckningsoptioner samt inbetald teckningspremie, vilket tillfört bolaget cirka 8 MSEK.
  • Resultat per aktie för kvartalet före / efter utspädning uppgick till -0,1 (-0,2) SEK.
  • Eget kapital per aktie uppgick vid periodens slut till 0,3 (0,6) SEK.
  • Soliditeten vid periodens slut uppgick till 76,8 (84,1) procent.

Väsentliga händelser under kvartalet

  • Det nyttjades 12 075 688 teckningsoptioner av serie TO10B, motsvarande cirka 34,1 procent av utestående teckningsoptioner. Teckningskursen uppgick till 0,26 SEK per B-aktie och tillförde bolaget cirka 3,1 MSEK före emissionskostnader.
  • iZafe har tecknat ett samarbetsavtal med ApoEx där Dosell är den enda läkemedelsroboten på marknaden som klarar av deras påsar. ApoEx levererar dospåsar till 3 500 patienter och sjukhus i flera av landets regioner. I Stockholm producerar företaget de dospåsar som bland annat Aleris använder sig av i sina sjukvårdsleveranser.
  • iZafe tillträder förvärvet av Pilloxa, genomför en riktad emission av aktier motsvarande 5 MSEK och teckningsoptioner till kvalificerade investerare samt emitterar vederlagsfria teckningsoptioner till befintliga aktieägare.

Väsentliga händelser efter kvartalets utgång

  • Dosell implementeras i två nya kommuner i Sverige med partnern Careium.
  • iZafe har beviljats ett nytt patent för tryggare läkemedelshantering i hemmet.

KOMMENTARER FRÅN VD
I föregående rapport nämnde jag att vi fokuserar på ett antal viktiga områden för att säkerställa en framgångsrik framtid. Det var att stärka ägarkretsen, strategiska förvärv för att bredda vårt erbjudande, hantering av personlig data och integrering mot välfärdsplattformar samt expansion mot nya marknader och samarbeten med befintliga och nya partners.

Under kvartalet har vi levererat inom flera av dessa områden.
Genom förvärvet av Pilloxa, så når vi den vision vi har strävat efter, att kunna ge rätt medicin i rätt tid på fler sätt än enbart medicinering via dospåse. Vi kan nu digitalisera hela patientresan där vi tillsammans erbjuder en lösning som ger full kontroll över medicineringen, inklusive påminnelser, larm och statistik, så att medicinen tas som den ska. Därmed förbättras livskvaliteten och säkerheten för patienten, samtidigt som vi kan säkerställa all data kring medicinering som gör att vi kan erbjuda marknaden ett unikt tjänsteutbud. Denna bild visar hur vi som bolag vill erbjuda marknadsledande lösningar för våra partners som med hjälp av våra produkter och tjänster kan få data kring medicineringen, som sedan kombineras med värden från andra sensorer så att man framåt kan erbjuda en mer proaktiv vård.

Vi har säkerställt ett antal nya aktieägare som tror på bolaget på lång sikt och som kan stötta bolagets expansion på den internationella marknaden.

Tack vare vår nya unika lösning och paketering så har vi väckt stort intresse, både nationellt och internationellt, och vi har långt gångna dialoger med ett flertal aktörer i nya europeiska länder. Där vi ser att försäljningen inom kort skall generera ökade kassaflöden.

Parallellt har vi också fortsatt arbetet med att sänka kostnaderna och optimera effektivitet och lönsamhet.

iZafe har även beviljats ett nytt patent för en ännu tryggare hantering av läkemedel i hemmet kopplat till våra nya unika digitaliserade lösningar för att säkerställa rätt medicin i rätt tid, vilket stärker vår position på marknaden.

Vid förvärvet av Pilloxa genomförde vi en riktad emission för att säkerställa kortsiktig likviditet, och nu i början av mars kommer vi att genomföra en optionsinlösen för att ge våra befintliga aktieägare möjligheten att stötta bolaget.

Med en stärkt efterfrågan på våra unika lösningar internationellt och med sänkta kostnader, så ser jag optimistiskt på att de likvider som kommer in i samband med optionsinlösen medför att vi inte behöver ta in mer externt kapital innan vi blir kassaflödespositiva. Säker hantering av läkemedel är bra för användare, vårdgivare och samhälle. Att bidra till lösningar på ett stort globalt problem ger oss i iZafe inspiration och energi. Jag är stolt för det hårda arbete vi hittills utfört med ett fåtal anställda och ser fram emot en spännande framtid för vårt bolag.

Kontakter

Anders Segerström, Verkställande Direktör
Mail:
Mobilnummer: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-post:
www.izafe.se/investor-relations/

Om iZafe Group AB (publ)

iZafe Group är ett renodlat Life-Science företag som leder utvecklingen av digital läkemedelsdispensering. Bolaget bedriver forskning, utveckling och marknadsföring av digitala medicinska lösningar och tjänster för tryggare läkemedelshantering i hemmet. iZafe Groups läkemedelsrobot Dosell används för att minska risken för felmedicinering i hemmet, avlasta den offentliga vården, öka livskvaliteten för patienten samt skapa en tryggare miljö för anhöriga. Kunderna utgörs idag av offentliga och privata vårdgivare i Sverige, Norden och globalt. iZafe Group säljer primärt via väletablerade partners som redan besitter långa och djupa kundrelationer med de prioriterade kundgrupperna. Huvudkontoret ligger i Stockholm.

Bolaget är noterat på NASDAQ First North Premier Growth Market. FNCA Sweden AB är bolagets Certified Adviser. Telefon: +46 (0) 8 528 00 399. E-post: . Ytterligare information finns på www.izafe.se/investor-relations/.

Denna information är sådan information som iZafe Group är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning. Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 2023-02-03 08:30 CET.

Bifogade bilder

Unikt Tjänsteutbud

Bifogade filer

iZafe Groups kvartalsrapport Q4

iZafe Groups kvartalsrapport Q4
Unikt Tjänsteutbud

iZafe has been granted a new patent for safer medication handling at home

iZafe Group AB (publ.) announces that the Swedish Patent and Registration Office (PRV) intends to grant another patent application of iZafe Group. The patent, titled "System and procedure for medication delivery arranged to adjust a pre-defined and pre-packaged medication dose based on a patient-specific parameter," applies to the company's technology for medical and digital security solutions to create safer medication management in the home.

"This patent gives us additional protection in Sweden for medication handling at home. After the acquisition of Pilloxa, we are able to offer solutions for safe medication for the entire patient journey, which in practice means the following steps:
• Pill jars or other loose medicine in syringes, tablets or liquid form. Where, with the help of our app, we remind, show statistics and can send alarms.
• Sorting in "dosett" where we offer a smart connected version that, with the help of our app, helps with sorting, reminders, alarms and statistics.
• Medication in sachets where, with the help of Dosell, we automate the entire process in the medication.
With this patent, we can also create a unique solution for safer medication handling in the home and addressing a significent and increasing demand" says Anders Segerström, CEO of iZafe Group.

Contacts

Anders Segerström, Chief Executive Officer 
E-mail:
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: 
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

Attachments

iZafe has been granted a new patent for safer medication handling at home

iZafe has been granted a new patent for safer medication handling at home

The medication robot Dosell is being implemented in two new municipalities

iZafe Group (publ.) hereby announces that the partner Careium Sweden AB is now starting the implementation of Dosell in two more municipalities in Sweden.

The municipalities, which together have approximately 13,500 residents aged 65 and over, initially start with 10 Dosells and then gradually increase the number.

Lack of adherence to medication is a major societal problem, which requires large resources to deal with. Dosell solves medication management in an efficient way and thus frees up the staff's time for care.

"We look forward to continuing the implementation of Dosell in more municipalities in the future and thereby working for greater independence for care recipients," says Martin Puumalainen Director Nordics and International for Careium AB

About Careium
Careium is one of the leading players in welfare technology in Europe and around 400,000 people use their services. The vast majority of these are connected to one of the company's four alarm centers in Sweden, Norway and Great Britain. The alarm centers receive more than 25,000 alarms a day. Read more at careium.com

About Dosell
The medicinal robot Dosell is a Swedish-made digital aid for safer medication at home and for people living in nursing homes. Dosell is integrated into welfare platforms and is sold as one of several integrated digital aids via partners.
In a Swedish report, it is estimated that 3,000 Swedes die annually from drug-related injuries and that 6–16 percent of hospital admissions are drug-related. The costs for drug-related injuries that can be avoided are estimated at SEK 5.6–24.6 billion per year.
Dosell notifies the patient when it's time to take the medicine, and if the medicine is not taken despite the reminders, Dosell alerts healthcare professionals or relatives who can quickly prevent an injury and improve compliance, thus minimizing drug-related injuries.
Read more at www.dosell.com

Contacts

Anders Segerström, Chief Executive Officer 
E-mail:
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: 
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

Attachments

The medication robot Dosell is being implemented in two new municipalities

The medication robot Dosell is being implemented in two new municipalities

iZafe resolves on the record date for allotment of, and first day of trading in, warrants of series TO13B

As announced by press release on November 28, 2022, the Board of Directors of iZafe Group AB (publ) ("iZafe" or the "Company") has decided to distribute warrants free of charge to shareholders in the Company. The record date for allotment of warrants of series TO13B has been set to December 23, 2022. The exercise period to subscribe for new shares with the support of warrants of series TO13B will be from and including February 23, 2023, to and including March 8, 2023. The first day of trading in the warrants of series TO13B on Nasdaq First North Growth Market will be on December 28, 2022.

As announced by press release on November 28, 2022, iZafe has completed a directed issue of shares and warrants of series TO13B (the “Directed Issue”). In order to give existing shareholders in the Company the opportunity to compensate for the dilution the Directed Issue entails, the Board of Directors of iZafe has also decided to issue warrants of series TO13B (same series as in the Directed Issue) to the Company, which then are allotted free of charge to the shareholders in the Company.

The record date to receive warrants of series TO13B has been set to December 23, 2022. Therefore, the last day of trading in the Company’s share including the right to receive warrants is December 21, 2022, and the first day of trading in the Company’s share excluding the right to receive warrants is December 22, 2022.

The Company’s existing shareholders will receive one (1) free warrant of series TO13B for every two (2) shares held in the Company on the record date.

Terms and information regarding warrants of series TO13B

Each warrant of series TO13B gives the right to subscribe for one (1) new share in the Company during the period from and including February 23, 2023, to and including March 8, 2023. The subscription price for shares of series B supported by warrants of series TO13B amounts to 70 percent of the volume weighted average price of the Company's share on the Nasdaq First North Premier Growth Market during the period from and including February 9, 2023, to and including February 22, 2023, however, the share's minimum quota value (currently SEK 0.20) and a maximum of SEK 0.30.

41,666,668 warrants of series TO13B are allotted to the investors in the Directed Issue and 76,890,165 warrants of series TO13B are allotted to the shareholders of the Company. In the event of full utilization of warrants of series TO13B, the Company can receive an additional maximum of approximately SEK 35.6 million, depending on the subscription price. If all of the Company's 118,556,833 issued warrants of series TO13B are exercised, the number of shares in the Company will increase by 118,556,833 shares, from 153,780,330 shares to 272,337,163 shares, and the share capital will increase by SEK 23,711,366.60, from SEK 30,756,066.00 to SEK 54,467,432.60. Which entails a total dilution for the Company's existing shareholders of approximately 43.53 percent of the numbers of shares and approximately 42.69 percent of the votes.

Advisors
Mangold Fondkommission AB is the finacial advisor to iZafe in connection with the warrants of series TO13B.

Contacts

Anders Segerström, Chief Executive Officer 
E-mail:
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: 
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

Attachments

iZafe resolves on the record date for allotment of, and first day of trading in, warrants of series TO13B

iZafe resolves on the record date for allotment of, and first day of trading in, warrants of series TO13B

Change of Certified Adviser (CA) to Mangold Fondkommission AB

iZafe Group AB (publ) hereby announces that the company has entered into an agreement with Mangold regarding the service as Certified Adviser.

Mangold will take over as Certified Adviser (CA) on 1 April 2023. Until then, FNCA will continue to act as Certified Adviser for the company.

Contacts

Anders Segerström, Chief Executive Officer 
E-mail:
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: 
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

Attachments

Change of Certified Adviser (CA) to Mangold Fondkommission AB

Change of Certified Adviser (CA) to Mangold Fondkommission AB

iZafe acquires Pilloxa, carries out a directed issue of shares and warrants to qualified investors and issues warrants free of charge to existing shareholders

iZafe Group AB (publ) ("iZafe" or the "Company") has today entered into a share purchase agreement with the owners of Pilloxa AB ("Pilloxa") regarding the acquisition of all outstanding shares of Pilloxa in accordance with the letter of intent communicated by press release on August 18, 2022. Access to the shares in Pilloxa was completed today. iZafe has also successfully completed a directed issue of 20,833,334 units, each unit consisting of one (1) share and two (2) warrants of series TO13B. The subscription price per unit amounts to SEK 0.24, corresponding to a price per share of SEK 0.24 as the warrants are issued free of charge and the Company is thereby provided with approximately SEK 5 million before transaction costs (the "Directed Issue"). Qualified investors such as Jan Hardenborg, Eva Redhe, Fredrik Sjödin, Filippa Lindström, Karin Forseke, Peter Jörgensen, Lars Wedenborn and Mangold Fondkommission have through subscription commitments undertaken to participate in the Directed Issue. The Company has also decided to distribute 76,890,165 warrants of series TO13B to all shareholders in the Company after the acquisition of Pilloxa to capitalize the Company and to compensate for the dilution from the Directed Issue.

The Directed Issue

The Board of Directors of iZafe has, with the support of the authorization received at the Extraordinary General Meeting on September 28, 2022, today decided to carry out a directed issue of 20,833,334 units with deviation from existing owners' preferential rights, each unit consists of one (1) share and two (2) warrants of series TO13B. The subscription price per unit amounts to SEK 0.24, corresponding to a price per share of SEK 0.24, the warrants are issued free of charge. The Company receives approximately SEK 5 million before deductions for transaction costs. The subscription price for the Directed Issue has been determined through arm's length negotiations with several strategic and long-term investors over a period of time. The subscription price corresponds to a discount of 10 percent in relation to the volume weighted average price of the Company's share on the Nasdaq First North Premier Growth Market during the last five (5) trading days, from and including November 22, 2022, to and including November 28, 2022, which amounted to approximately 0.262 SEK. The Board of Directors thus assesses the subscription price to be at market terms.

Each warrant of series TO13B gives the right to subscribe for one (1) new share in the Company during the period from and including February 23, 2023, to and including March 8, 2023. The subscription price for shares of series B supported by warrants of series TO13B amounts to 70 percent of the volume weighted average price of the Company's share on the Nasdaq First North Premier Growth Market during the period from and including February 9, 2023, to and including February 22, 2023, however, the share's minimum quota value (currently SEK 0.20) and a maximum of SEK 0.30.

Background and motive for the Directed Issue

In order to satisfy the demand from existing customers, as well as meet the demand from new customers, iZafe deems it necessary to raise additional capital. iZafe intends to use the issue proceeds from the Directed Issue to increase sales of Dosell and Pilloxa's solutions.

More specifically, the Company intends to use the issue proceeds for:

  • Sales efforts of Dosell against Pilloxa's established customers and network.
  • Sales efforts of Pilloxa’s solutions towards iZafe’s partner network.
  • Integration between Dosell and Pilloxa's system and product.

The reason for that, and for the deviation from the shareholders' preferential rights, is to strengthen the Company's shareholder base with long-term strategic and qualified investors and at the same time in a quick and cost-effective way finance the Company's need for working capital, which has been slightly increased with the acquisition of Pilloxa. Also, the Board of Directors considers implementing a rights issue in current market conditions would entail a risk that the Company fail to meet its capital needs and by so fail to maintain an optimal capital structure. The Company's Board of Directors has made an overall assessment and carefully considered the possibility of raising capital through a rights issue. The Board of Directors has taken into account, among other things the high number of recent rights issues on the Nasdaq First North Premier Growth Market, and that the additional cost of a rights issue, such as advisory fees and underwriting compensation, would be unproportional to the limited size of the short term required capital. The conclusion of the Board of Directors' assessment is that the Directed Issue is objectively the best alternative for the Company and its shareholders.

The acquisition of Pilloxa

Pilloxa has developed a technology platform to support better medication adherence that pharmaceutical and healthcare companies use to design digital patient supports. The acquisition creates a new company in digital health that is well positioned to become a leading player in better and safer drug use. The purchase price amounts to approximately SEK 13.75 million and is paid through a directed offsetting issue of a total of 50,000,000 shares in iZafe ("Compensation Shares"). The subscription price for the Compensations Shares amounts to SEK 0.275. The basis for the subscription price is the share's market value based on the closing price for the Company's share of series B on the Nasdaq First North Premier Growth Market on Friday November 25, 2022.

  • Through the acquisition of Pilloxa, we are taking an important step towards our vision of improved health with better adherence. This creates an attractive and complete offer, access to a larger customer base and more sales channels. Through the Directed Issue, we are bringing in more strong owners to iZafe, and the warrants awarded to all shareholders are expected to provide a capital injection at the beginning of 2023. We will now increase the pace of sales of the joint company's products and services towards all our different customer categories. Together, we are creating a very strong offer within the framework of digital health, says Anders Segerström, CEO of iZafe.
  • With Pilloxa's digital offering and long-term collaboration with the pharmaceutical industry, we can together offer a comprehensive solution for patients, healthcare staff and the pharmaceutical industry. Pilloxa's promise to our customers, SME pharmaceutical companies, is a complete digital solution for patient support within one month of the first customer meeting. We are therefore used to rapid integrations and will immediately begin work on offering a joint digital solution, says Helena Rönnqvist, CEO at Pilloxa.

Incorrect or deficient medication is a major and costly problem for the individual, healthcare and for pharmaceutical companies, and costs society significant sums. Offering patients support to take their medication correctly has been shown to be an effective way to achieve better medical outcomes. Both iZafe and Pilloxa today offer solutions that support patients in safe medical treatment. The merger means a broader and more attractive offer to healthcare providers, patients, the pharmaceutical industry, and consumers, broadens the customer base and is expected to contribute to accelerated market penetration through clear sales and margin synergies.

Warrants to existing shareholders of iZafe

The Company has decided to distribute 76,890,165 warrants of series TO13B to all shareholders in the Company after the acquisition of Pilloxa in order to capitalize the Company and to compensate for the dilution from the Directed Issue. The warrants are subscribed by the Company and will be distributed free of charge to existing shareholders in the Company, where the Company's existing shareholders will receive one (1) free warrant of series TO13B for every two (2) shares held in the Company on the record date. The Board of Directors has been authorized to determine the record date, thus information about the record date for the allotment of warrants of series TO13B will be communicated via a separate press release.

Each warrant of series TO13B gives the right to subscribe for one (1) new share in the Company during the period from and including February 23, 2023, to and including March 8, 2023. The subscription price for shares of series B supported by warrants of series TO13B amounts to 70 percent of the volume weighted average price of the Company's share on the Nasdaq First North Premier Growth Market during the period from and including February 9, 2023 to and including February 22, 2023, however, the share's minimum quota value (currently SEK 0.20) and a maximum of SEK 0.30.

Terms, number of shares, share capital and dilution

Through the acquisition of Pilloxa, the number of shares in the Company increases by 50,000,000 B shares, from 82,946,996 shares (600,000 A shares and 82,346,996 B shares) to 132,946,996 shares, and the share capital will increase by SEK 10,000,000.00, from SEK 16,589,399.20 to SEK 26,589,399.20. The issue of shares as a result of the acquisition of Pilloxa entails a dilution for the Company's existing shareholders of approximately 37.61 percent.

The Directed Issue comprises 20,833,334 units, each unit consisting of one (1) share and two (2) warrants of series TO13B. The Directed Issue will increase the number of shares in the Company by 20,833,334 shares, from 132,946,996 shares to 153,780,330 shares, and the share capital will increase by SEK 4,166,667.80, from SEK 26,589,399.20 to SEK 30,756,066.00. The Directed Issue entails a dilution for the Company's existing shareholders of approximately 13.55 percent.

As a result of the acquisition and the Directed Issue, the total number of shares in the Company will increase by 70,833,334 shares, from 82,946,996 shares to 153,780,330 shares, and the share capital will increase by SEK 14,166,666.80, from SEK 16,589,399.20 to 30,756,066.00 SEK. Which entails a total dilution for the Company's existing shareholders of approximately 46.06 percent.

41,666,668 warrants of series TO13B are allotted to the investors in the Directed Issue and 76,890,165 warrants of series TO13B are allotted to the shareholders of the Company after the completion of the acquisition and the Directed Issue. In the event of full utilization of warrants of series TO13B, the Company can receive an additional maximum of approximately SEK 35.6 million, depending on the subscription price. If all of the Company's 118,556,833 issued warrants of series TO13B are exercised, the number of shares in the Company will increase by 118,556,833 shares, from 153,780,330 shares to 272,337,163 shares, and the share capital will increase by SEK 23,711,366.60, from SEK 30,756,066.00 to SEK 54,467,432.60. Which entails a total dilution for the Company's existing shareholders of approximately 43.53 percent.

Advisors
Mangold Fondkommission AB is the finacial advisor to iZafe in connection with the acquisition of Pilloxa and the Directed Issue.

Contacts

Anders Segerström, Chief Executive Officer 
E-mail:
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: 
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

This information is information that iZafe Group is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-11-28 19:30 CET.

Attachments

iZafe acquires Pilloxa, carries out a directed issue of shares and warrants to qualified investors and issues warrants free of charge to existing shareholders

iZafe acquires Pilloxa, carries out a directed issue of shares and warrants to qualified investors and issues warrants free of charge to existing shareholders

iZafe begins collaboration with ApoEx for enhanced patient safety

iZafe Group (publ.) hereby announces that it has signed a cooperation agreement with ApoEx AB, which is a supplier of pharmacy services, systems and dosage bags to privately and publicly run healthcare providers.

“iZafe and the medicine robot Dosell are the only products on the market that can handle the dose bags that we deliver to our customers in outpatient and inpatient care. We are happy to develop the collaboration with iZafe, which is completely in line with our business concept of offering technical solutions to customers in public and private healthcare”, says John Patrick Berlips, licensed physician and founder of ApoEx.

ApoEx supplies dose bags to 3,500 patients and hospitals in several of the country's regions. In Stockholm, the company produces the sachets that, among others, Aleris uses in its healthcare deliveries.

“ApoEx offers smart comprehensive solutions of goods and services for both private and public healthcare and is therefore the right partner for us. As iZafe is currently in an expansive phase, our strategic partnerships are absolutely crucial for us. With these collaborations, we can more effectively develop successful solutions together”, says Anders Segerström, CEO of iZafe.

About ApoEx
ApoEx was founded in 2010 with the aim of simplifying and improving care. We have developed most solutions in close dialogue with our customers and the business is characterized by customer-driven innovation and the attitude that nothing is impossible. Over the years, thousands of healthcare companies in the private and public sector have chosen ApoEx as their strategic partner for the supply of medicines and consumables.

Contacts

Anders Segerström, Chief Executive Officer 
E-mail:
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: 
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

Attachments

iZafe begins collaboration with ApoEx for enhanced patient safety

iZafe begins collaboration with ApoEx for enhanced patient safety

iZafe Group’s quarterly report Q3, July-September 2022

iZafe Group AB (publ.) – presents today, November 7, its report for the third quarter of 2022.

Summary of financial performance

  • Net sales for the quarter amounted to SEK 75 (38) thousand. The quarter's net sales consist of revenues related to the sale of the digital pharmaceutical robot Dosell.
  • Operating profit for the quarter amounted to SEK -5,680 (-5,342) thousand.
  • Profit after financial items for the quarter amounted to SEK -5,751 (-6,183) thousand.
  • Cash flow for the period amounted to SEK -4,513 (-6,475) thousand.
  • Earnings per share for the quarter before / after dilution amounted to SEK -0.1 (-0.2).
  • Equity per share at the end of the period amounted to SEK 0.3 (1.5).
  • The equity ratio at the end of the period was 75.0 (62.3) percent.

Significant events during the quarter

  • The company has signed a cooperation agreement with the welfare platform Avanto Care. The collaboration means that iZafe's products are integrated with Avanto Care's platform and gives the opportunity to work more proactively with the users' medication.
  • With our partners Careium AS and Hepro AS, 20 and 25 Dosell have respectively been implemented in new municipalities in Norway.
  • Together with Aleris, the Company has started a pilot project for safer medication management. The goal is to introduce Dosell for the patient group that has advanced healthcare at home. During the quarter, 30 patients were introduced to the pharmaceutical robot.

Significant events after the end of the quarter

  • During quarter four 2022, 12,075,688 warrants of series TO10B were exercised, representing approximately 34.1 percent of outstanding warrants. The subscription price amounted to SEK 0.26 per B-share and raised approximately SEK 3.1 million for the company before issue costs
  • The company has signed a cooperation agreement with Medcam AB, which sells medical devices to the healthcare sector in the Nordic region and Europe. The primary focus will be on the Dutch market, but the potential for the company to enter several countries exists in the near future.

COMMENTS FROM THE CEO
A lot has happened in the last quarter and we continue to make strides on our growth journey – both in the Swedish and European markets.
There is a growing demand for products and services that enable more digital care where medication and adherence are crucial.

Our Dosell vending machine continues to do well across the board and we are pleased to see strong demand and positive sales for Dosell consumer through Apoteket AB. The packaging and sales of our consumer product have been crucial in moving forward in dialogues with potential partners in other European countries. We have now accumulated enough experience and documentation to streamline the processes and reduce the costs associated with selling and marketing Dosell to consumers.

Our entire business concept is based on sales through specific partners who handle sales, warehousing, logistics and marketing. With a focus on ensuring quality in small volumes at first, we will be able to scale up the volume and sales of many of our partners in more markets as early as next year.
We have also started the implementation of Dosell at Aleris ASIH (Advanced Home Healthcare) which is very exciting. The whole ASIH market relies on a different type of Dosell than the procured Dosell at regional level. It has a different design that makes it very difficult for the drug robots to handle. We can proudly say that we are the only pharmaceutical robot on the Swedish market that can handle these dose bags.

We have a clear vision to offer proactive holistic health for many more providers and patients, with a focus on these four elements:

  1. Securing established and professional owners who can support the company with long-term external funding
  2. Strategic acquisitions that broaden our offering and portfolio ensuring the right medicine at the right time
  3. 3.Managing personal data and ensuring that the necessary integration work is implemented
  4. Internationalization towards new markets and together with both existing and new partners

Since October, we have a new Board in place that will help us to realize the action plan ahead. We have secured expertise and networks around finance, digitization, GDPR, sensitive data management and legal requirements. There we now have a clear strategy and plan for acquisitions, integrations with other wellbeing platforms, sales and internationalization.

The potential acquisition of Pilloxa is very interesting as we see that there is a strong demand around the ability to ensure adherence through all stages of the patient journey and to be able to integrate data into wellbeing platforms and home monitoring. The status on this is that we have completed due diligence and are now in the final stages of negotiations.

Another milestone during the quarter is our entry into the Dutch market. The Netherlands is an important market for us as they are the foremost pioneers in dose packaged medicine. The majority of all manufacturers of dose packaging machines are based in the Netherlands, which means that once we have been successful there, there will be positive knock-on effects throughout Europe.

Finally, I would like to mention that we are in dialogue with several other players in key markets in Europe, with whom we hope to have a clear agreement shortly. In this way, iZafe can in the future contribute broadly to a more proactive holistic approach to health, resulting in better health for more people. Socially sustainable value for society – that's really important.

Contacts

Anders Segerström, Chief Executive Officer 
E-mail:
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: 
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

This information is information that iZafe Group is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-11-07 08:30 CET.

Attachments

IZafe Group Q3 ENG

IZafe Group Q3 ENG
Webbdesign av Comlog Webbyrå Stockholm